CHRNA1
Acetylcholine receptor subunit alpha
As of the edition of 20 October 2026, CHRNA1 (acetylcholine receptor subunit alpha, UniProt P02708) has 14 drugs tested at it and 10 companies on the list, 0 on route A and 2 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P02708
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- At a membrane
- Solved structures
- 27
- Disease areas
- Nervous system; Lungs and airways; Digestive system; Urinary and reproductive; Pregnancy and women's health; Heart and blood vessels; Cancer; Mental health
- Registered trials of its drugs
- 218
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 13 |
| Withdrawn from market | 1 |
| Total | 14 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Rocuronium | Marketed | Phase 4 | none listed |
| Cisatracurium | Marketed | Phase 4 | none listed |
| Suxamethonium | Marketed | Phase 4 | none listed |
| Atracurium | Marketed | Phase 4 | none listed |
| Vecuronium | Marketed | Phase 4 | none listed |
| Mivacurium | Marketed | Phase 4 | none listed |
| Pipecuronium | Marketed | Phase 4 | none listed |
| Tubocurarine | Marketed | No phase stated | none listed |
| Decamethonium | Marketed | No phase stated | none listed |
| Doxacurium | Marketed | No phase stated | none listed |
| Gallamine | Marketed | No phase stated | none listed |
| Metocurine | Marketed | No phase stated | none listed |
12 of 14 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route B | 2 |
| Engaged | 2 |
| Undetermined | 6 |
| Total on the list | 10 |
The other 8 companies at CHRNA1
In the product10 companies in all; 8 are not named here, and no score is.
See the 10 companies at CHRNA1, ranked, with the facts behind eachRequest access. Nothing is shown until you do.